Moderators: Elvis, DrVolin, Jeff
Staggering Surge Of NYers Dying In Their Homes Suggests City Is Undercounting Coronavirus Fatalities
BY GWYNNE HOGAN, WNYC
APRIL 7, 2020 6:00 A.M. • 133 COMMENTS
[...]
As of Monday afternoon, 2,738 New York City residents have died from ‘confirmed’ cases of COVID-19, according to the city Department of Health. That’s an average of 245 a day since the previous Monday.
But another 200 city residents are now dying at home each day, compared to 20 to 25 such deaths before the pandemic, said Aja Worthy-Davis, a spokeswoman for the medical examiner’s office. And an untold number of them are unconfirmed.
Listen to reporter Gwynne Hogan discuss her story on WNYC:
That’s because the ME’s office is not testing dead bodies for COVID-19. Instead, they’re referring suspected cases to the city’s health department as “probable.”
“If someone dies at home, and we go to the home and there [are] signs of influenza, our medical examiner may determine the cause of death was clearly an influenza-like illness, potentially COVID or an influenza-like illness believed to be COVID,” said Worthy-Davis. “We report all our deaths citywide to the health department, who releases that data to the public.”
But the health department does not include that number in the official count unless it is confirmed, a spokesman said.
“Every person with a lab confirmed COVID-19 diagnosis is counted in the number of fatalities,” the spokesman, Michael Lanza, said in an email. He said the city's coronavirus death tally does not break down who died at home versus who died in a hospital from the virus.
“While undiagnosed cases that result in at-home deaths are connected to a public health pandemic...not all suspected COVID-19 deaths are brought in for examination by OCME, nor do we provide testing in most of these natural at-home deaths,” Lanza said.
Typically, when someone dies at home, a loved one, acquaintance or neighbor calls the police or 911. First responders call in the medical examiner, who conducts a review to determine if there was foul play, then records a cause of death.
Worthy-Davis could not immediately provide a tally of how many “probable” COVID-19 deaths have been referred to the Health Department. The health department also could not provide the number of “probable” COVID deaths certified by OCME.
If a person had been tested before death, that record would be passed along, said Worthy-Davis. But testing protocols have generally excluded victims who are not hospitalized.
Statistics from the Fire Department, which runs EMS, confirm a staggering rise in deaths occurring at the scene before first responders can transport a person to a hospital for care.
The FDNY says it responded to 2,192 cases of deaths at home between March 20th and April 5th, or about 130 a day, an almost 400 percent increase from the same time period last year. (In 2019, there were just 453 cardiac arrest calls where a patient died, according to the FDNY.)
[...]
JackRiddler » Tue Apr 07, 2020 8:13 pm wrote:.
I'm pretty sure the 600 number is for NYC, five boroughs, not the state. And if not, then 500 or more of the 600 will still be in NYC, where the dense clusters are.
alloneword » Tue Apr 07, 2020 4:01 pm wrote:JackRiddler » Tue Apr 07, 2020 8:13 pm wrote:.
I'm pretty sure the 600 number is for NYC, five boroughs, not the state. And if not, then 500 or more of the 600 will still be in NYC, where the dense clusters are.
The current data from 'covidtracking' gives the exact figure (4,758) for New York State as was quoted by Cuomo. The figure for NYC is given as 2,738, 56% of the state total.
(will add more later...)
Gov. Andrew M. Cuomo said on Tuesday that 731 people had died of the virus since Monday, the state’s highest one-day total yet by more than 100.
operator kos » Tue Apr 07, 2020 1:31 pm wrote:alloneword » Tue Apr 07, 2020 1:11 pm wrote:Yes. Hence my asking.
79,091 deaths / 1,390,511 cases = 5.69% mortality rate. It's right there in big red and white numbers at the top of the first link, so I'm not sure what the confusion is.Severe: 14% (6168 cases)
Critical: 5% (2087 cases)
It's right under "Key Findings" near the top of the second link, so I'm not sure what the confusion is.
The influence of Navarro’s memos on Trump’s approach isn’t clear. But, usefully in this moment, he can point to ways in which he was ahead of the curve. The January memo contrasted the costs of addressing coronavirus with the costs of the seasonal flu, noting how the two differed in both scale and danger. His February memo warned of an “increasing probability of a full-blown COVID-19 pandemic that could infect as many as 100 million Americans, with a loss of life of as many as 1-2 million souls” — an estimate in line with later estimates, including one from Imperial College London that reportedly helped push the administration to take stronger action in addressing the virus.
“Would you take [the drug hydroxychloroquine] if you got sick?” Navarro asked CNN's John Berman.
“Would I take it if I got sick? I would listen to my doctor about whether or not I should take it,” Berman replied. “I would consult my doctor, not someone involved with trade policy. Do you want an internist striking trade deals?"
Also, READ: Army germ research lab in Md. that was working on Ebola treatment is shut down by CDC
Researchers at the Vancouver Infectious Diseases Centre are recruiting coronavirus-positive participants in a clinical study.
The study, which is spearheaded by the Montreal Heart Institute Research Centre, looks at whether an existing drug can reduce the risk of lung complications and death.
Experts said the majority of COVID-19 cases are mild but some patients develop complications and appear to have a "major inflammatory storm."
The study, called colcorona, will test patients using colchicine, which is a drug typically used to treat gout.
"It is a powerful anti-inflammatory agent and we believe that it is key to prevent the complications of COVID-19," said Dr. Jean-Claude Tardif with the MHI. Tardif said the institute recently tested 4,700 patients in another colchicine study.
"We know that it is safe," he said. "We have demonstrated the safety and tolerability of colchicine, so there's no doubt about that."
They are currently recruiting participants who meet the following criteria:
show symptoms of COVID-19;
40 years and older;
not hospitalized;
willing to take the drug or placebo daily for 30 days;
and willing to participate in two follow-up calls.
Tardif said in an "ideal world" it would be preferred if the patients have been swabbed and tested positive for the virus, but he said people who live in the same household as someone who's tested positive and are showing symptoms, and people who are typically healthy and suddenly show signs of COVID-19 (cough, shortness of breath, fever and fatigue) would also be accepted.
"A few months from now, when the dust settles, hopefully we will do a blood test to confirm by antibodies that these patients indeed had the disease, so not every participant needed to have tested positive," he said.
MHI has partnered with researchers in Vancouver and New York and soon, Ontario, Spain, California will be added to the list.
"We want this study to be completed rapidly because we are actually very optimistic that we may provide a significant part of the solution to this horrible situation that we're all faced with in the world," he said.
Participants will not have to leave their homes, he said, adding the drugs will be delivered to the door and all the correspondences with nurses are done over the phone.
A world-class discovery in Montreal
November 16, 2019
The COLCOT clinical trial demonstrates that it is possible to reduce the risk of cardiovascular events with a low-cost drug already available.
The Montreal Heart Institute (MHI) today announced results from the COLchicine Cardiovascular Outcomes Trial (COLCOT). The clinical trial compared colchicine to placebo on top of standard of care in preventing ischemic cardiovascular events in patients who recently suffered from a heart attack (myocardial infarction). In this study, patients receiving colchicine 0.5mg daily had a significantly lower rate of ischemic cardiovascular events (first and recurrent) than those on placebo1.
These results were published today in the prestigious New England Journal of Medicine (NEJM) and simultaneously presented at the American Heart Association (AHA) Late-Breaking Scientific Session.
In summary, colchicine significantly reduces the risk of a first ischemic cardiovascular event and of total ischemic cardiovascular events by 23% and 34% respectively in addition to standard of care in patients with a recent myocardial infarction (MI).
The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke or urgent hospitalization for angina requiring coronary revascularization1. Patients were also treated according to national guidelines that included the intensive use of statins1.
The trial demonstrated that the treatment with colchicine reduced by:
• 23% the risk of a first event of the primary efficacy endpoint;
• 34% the risk of total (first and recurrent) events of the primary efficacy endpoint;
• 29% the risk of a first event of the primary efficacy endpoint in patients who adhered to the protocol.
“The data from the COLCOT trial underscore the potential of colchicine as an efficient and critically needed therapy for reducing inflammation post-myocardial infarction to improve patient cardiovascular outcomes.” said Dr. Jean-Claude Tardif.
Researchers at the MHI have been testing Colchicine, an anti-inflammatory, which appears to reduce some of the grave effects of respiratory distress brought on by Covid-19. Respiratory failure caused by inflammation is the major cause of death from the virus. Colchicine is actually in pharmacies around the world. It is not a new drug and costs less than a dollar a day in prescription protocols. The study will involve 6000 people and the MHI has 40 nurses working 24/7 to take calls from people willing to participate and see if they meet the criteria. You can consult the website at COLCORONA.ORG.
MHI research director Dr. Jean-Claude Tardif told La Presse, “We have literally not slept for six days. Honestly, I think we have never seen this in history where a clinical study has been organized like this.What normally takes six months has been done in six days. The mobilization of doctors, researchers, private enterprises and governments has been absolutely extraordinary. If this works, and we stop the worst effects of the virus, it changes everything. The pressure on hospitals will be off as we won’t need to hospitalize so many and we won’t need quarantines.”
The MHI has been at the centre of a remarkable public/private partnership. The COLCORONA project was co-ordinated with the Centre for Clinical Studies of Montreal, financed by the Government of Quebec, the technological platform was developed by CGI, Pharmascience is producing the Colchicine and Telus installed the phone lines and communication platform.
Colchicine is a medication normally used to treat gout and Behçet’s disease. In gout, it is less preferred to NSAIDs or steroids. Other uses include the prevention of pericarditis and familial Mediterranean fever. It is taken by mouth. It is generally prescribed for a short-term and the MHI study will seek to determine if that is sufficient to reduce the risks of pulmonary complications and death related to Covid.
liminalOyster » 09 Apr 2020 06:54 wrote:Extremely interesting, thanks identity. Interestingly, I've heard there's a big pushback on ventilators because they stand to increase viral load (and are meant to help the lungs rather than oxygenate the blood.) Wonder how that might or might not relate to the politics of it all. More "dying at home" also means less "official deaths" and is presumably good for many parties.
Users browsing this forum: No registered users and 5 guests